The Top Ten Innovations In Podiatry
Dr. Lullove adds that the Hydrofera Blue Ready is easier to use than other foams in the same class and one can leave it in place for up to seven days. Dr. Lullove comments that using Endoform to reduce elevated matrix metalloproteinases and covering with Hydrofera Blue Ready foam to reduce bioburden and absorb exudate works well for his patients with venous leg ulcers and diabetic foot ulcers. Hollister notes that there is no hydration or secondary dressing required with the Hydrofera Blue Ready. The waterproof barrier keeps away moisture and bacteria, and the company adds that the dressing is non-cytotoxic and less expensive than most silver dressings.
“From my perspective, (Hydrofera Blue Ready) is taking a proven technology and reinventing the wheel, making it more user-friendly and more versatile as to how it can be used,” says Dr. Lullove.
Enluxtra™ Self-Adaptive Wound Dressing (OSNovative Systems). Wound conditions may be constantly changing but a new wound dressing reportedly can adapt to such changes and facilitate healing.
Enluxtra Self-Adaptive Wound Dressing dynamically balances the evolving moist wound environment, notes the manufacturer OSNovative Systems. The company says the dressing provides hydration or absorption depending on the needs of the wound and periwound skin. As the company notes, dry areas of the wound stay properly hydrated, the dressing absorbs and locks in fluid from exuding areas, and protects periwound skin from maceration.
Alexander Reyzelman, DPM, FACFAS, cites the Enluxtra as a “smart dressing” that one can use in various wounds such as diabetic foot ulcers, pressure ulcers, venous leg ulcers, and postoperative wounds. He notes an advantage in that the dressing can absorb a large amount of exudate and trap it within the dressing. Dr. Reyzelman says this allows autolytic debridement to occur by providing the appropriate wound environment.
“I have been impressed by the amount of exudate (Enluxtra) can absorb in the highly exudative venous leg ulcers. I’ve also been impressed with how it can be placed on a dry wound and keep the wound base moist,” says Dr. Reyzelman, an Associate Professor in the Department of Medicine at the California School of Podiatric Medicine at Samuel Merritt University in Oakland.
In addition, Dr. Reyzelman, the Co-Director of the UCSF Center for Limb Preservation, says Enluxtra can adapt to the various wound types such as highly exudative or minimally exudative wounds, and allow the wounds to progress to healing. He notes the dressing comes in various sizes and one can use it under compression or on surgical incisions in the operating room.
Key Advances In Podiatric Surgery
BioCartilage® (Arthrex). Osteochondral lesions of the talus can commonly occur after ankle sprains and one of the tried and true treatments for such lesions is bone marrow stimulation. A new micronized cartilage matrix can augment the bone marrow stimulation of osteochondral lesions of the talus.
Calling the BioCartilage “an excellent adjunct to bone marrow stimulation,” Alan Catanzariti, DPM, FACFAS, notes the product has an extracellular matrix native to articular cartilage including key components such as type II collagen, proteoglycans and additional cartilaginous growth factors. The manufacturer Arthrex notes that BioCartilage serves as a scaffold over a microfractured defect to provide a tissue network that can potentially signal autologous cellular interactions and improve the degree and quality of tissue healing within a properly prepared articular cartilage defect. Dr. Catanzariti adds that bone marrow elements will travel through the microfracture holes and interact with the scaffold instead of creating their own fibrin scaffold as typically happens with a bone marrow stimulation procedure.
Dr. Catanzariti uses the BioCartilage as an adjunct to bone marrow stimulation for virtually every osteochondral lesion of the talus less than 15 mm in diameter and cites encouraging preliminary results.